THE CLINICAL EFFICIENCY OF ADAMANTANE DERIVATIVE IN THE CORRECTION OF POSTENCEPHALITIC SOMATOGENIC ASTHENIA

An open, randomized clinical study in two groups of reconvalescents of tick-borne encephalitis suffered from postencefalitic somatogenetic asthenia. The first group was consisted of 14 patients who received adamantane derivatives - ladasten at a daily dose of 100 mg for 25 days. The second comparison group included 18 convalescents who were followed up without an prescription of Ladasten. Before and after treatment, the examination with the use of a Visual Analogue Scale fatigue, scale of subjective evaluation fatigue - Multidimensional Fatigue Inventory (MFI-20), Beck Depression Inventory, D. Spielberger's test (State-Trate-Anxiety-Inventory (STAI)), adapted for Russia by Yu. L. Khanin, a questionnaire for detection signs of autonomic changes. After receiving ladasten patients showed significant dynamics of the drop in scores accordingly to visual analogue scale fatigue by 2.5 times as opposed to those in the second group, where the fall was only by 1.4 times. In the first group there were also significant fall in scores of all scales MFI-20 (p = 0.0001), Beck Depression Scale (p = 0.001), Spielberger-Khanin test (p = 0.002) and the questionnaire for evidence of autonomic changes (p = 0.001). The obtained data suggest that Ladasten at a daily dose of 100 mg is highly effective drug with antifatigue, anxiolytic and vegetostabilizing effects and can be recommended in rehabilitation period to patients after the tick-borne encephalitis with manifestations of postencefalitic somatogenetic asthenia.

tick-borne encephalitis, postencephalitic somatogenic asthenia, adamantane derivative